Risk Factors and Clinical Outcomes of Hospitalized Covid-19 Patients with Diabetes Mellitus in a Tertiary Hospital

Jiselle Aimee Y. Bedia, Maria Honolina S. Gomez, Jean Uy-Ho, Erick S. Mendoza, Lizette Kristine F. Lopez

Apr 2025 DOI 10.35460/2546-1621.2023-0020     Access   

Abstract

Introduction: Patients with diabetes are at higher risk of developing severe COVID-19 infection with a two-fold increased risk of mortality. This study described the risk factors affecting clinical outcomes of confirmed COVID-19 patients with diabetes mellitus at the University of Santo Tomas Hospital, Manila, Philippines.

Method: This retrospective study included 204 patients with COVID-19 (34 with known type 2 diabetes and 2 with new-onset diabetes) from March to October 2020. Clinical characteristics and laboratory parameters were collected and analyzed in subjects with diabetes. A univariate logistic regression was used to calculate the odds ratios and 95% confidence interval (CI) for the patient’s risk factors associated with mortality or poor prognosis.

Results: Moderate COVID-19 infection occurred in 52.8% of type 2 diabetes mellitus (T2DM) patients and critical COVID-19 infection in 27.8%. All patients with critical COVID-19 infection presented with acute respiratory distress syndrome, half had concomitant septic shock and respiratory failure was observed in 27.8%. The average length of hospital stay was approximately 17.5 days. T2DM patients with established atherosclerotic cardiovascular disease (ASCVD) are 5.1 times (95% CI 1.2 to 21.4) more likely to develop severe or critical COVID-19 infection, and more likely to stay in the hospital for more than 14 days. HbA1c >8.5% is a potential risk (OR = 3.7, 0.6 to 21.6) for severe to critical disease. T2DM patients with concomitant coronary artery disease are 7.6 times (95% CI 1.3 to 43.4) more likely to stay longer (more than 14 days) as compared to those without existing coronary artery disease. Prior statin use was a significant risk factor for ICU admission (p-value 0.0341). Other potential risk factors affecting clinical outcomes are obesity (OR 3, 0.4 to 22.7), prior use of thiazolidinedione (OR 7.8, 0.5 to 126.7) or sodium-glucose transporter 2 (SGLT2) inhibitors (OR 7.5, 0.4 to 145) and prior use of anti-thrombotic (OR 4.6, 0.4 to 56.8). The recovery rate of T2DM patients hospitalized for COVID-19 infection was 86.1%.

Conclusion: Patients with T2DM are more vulnerable to COVID-19 infection. The presence of established ASCVD increases the likelihood of severe COVID-19 disease as well as longer length of hospital stay for more than 14 days. Early recognition and prompt treatment led to a favorable recovery rate.

Keywords: COVID-19, type 2 diabetes mellitus

  1. Nanditha A, Ma RCW, Ramachandran A, Snehalatha C, Chan JCN, Chia KS, et al. Diabetes in Asia and the Pacific: Implications for the global epidemic. Diabetes Care [Internet]. 2016;39(3):472–85. Available from: http://dx.doi.org/10.2337/dc15-1536 
  2. International Diabetes Federation (IDF) Atlas. 9th ed. Brussels, Belgium: International Diabetes Federation; 2019.
  3. Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidence. Diabetes Res Clin Pract [Internet]. 2020;166(108347):108347. Available from: http://dx.doi.org/10.1016/j.diabres.2020.108347 
  4. World Health Organization (WHO) Coronavirus Disease (COVID-19) Dashboard [Internet]. World Health Organization. [cited 2020]. Available from: https://covid19.who.int/?gclid=CjwKCAjwiOv7BRBREiwAXHbv3Nc7ib5xPDvo3St2jZ8x7ndqDnEv5rplPzuTZoh5MihUdQ31wOT10RoCkOYQAvD_BwE. 
  5. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol [Internet]. 2020;8(9):782–92. Available from: http://dx.doi.org/10.1016/S2213-8587(20)30238-2 
  6. Gupta R, Hussain A, Misra A. Diabetes and COVID-19: evidence, status and unanswered research questions. Eur J Clin Nutr [Internet]. 2020;74(6):1–7. Available from: http://dx.doi.org/10.1038/s41430-020-0652-1 
  7. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract [Internet]. 2020;162(108142):108142. Available from: http://dx.doi.org/10.1016/j.diabres.2020.108142 
  8. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr [Internet]. 2020;14(4):535–45. Available from: http://dx.doi.org/10.1016/j.dsx.2020.04.044 
  9. Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab [Internet]. 2020;22(10):1897–906. Available from: http://dx.doi.org/10.1111/dom.14099 
  10. Shi Q, Zhang X, Jiang F, Zhang X, Bimu C, Feng J, et al. Clinical characteristics, and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: A two-center, retrospective study [Internet]. American Diabetes Association. 2020. Available from: http://dx.doi.org/10.2337/figshare.12210008 
  11. Salva EP, Villarama JB, Lopez EB, Sayo AR, Villanueva AMG, Edwards T, et al. Epidemiological and clinical characteristics of patients with suspected COVID-19 admitted in Metro Manila, Philippines. Trop Med Health [Internet]. 2020;48(1):51. Available from: http://dx.doi.org/10.1186/s41182-020-00241-8 
  12. Buenaventura RD, Ho JB, Lapid MI. COVID-19 and mental health of older adults in the Philippines: a perspective from a developing country. Int Psychogeriatr [Internet]. 2020;30:1–5. Available from: http://dx.doi.org/10.1017/S0141610220000757 
  13. Elvira Arcellana A, Jimeno C. Challenges, and opportunities for diabetes care in the Philippines in the time of the COVID-19 pandemic. J ASEAN Fed Endocr Soc [Internet]. 2020;35(1):55–7. Available from: http://dx.doi.org/10.15605/jafes.035.01.04 
  14. Gamble A, Pham Q, Goyal S, Cafazzo JA. The challenges of COVID-19 for people living with diabetes: Considerations for digital health. JMIR Diabetes [Internet]. 2020;5(2):e19581. Available from: http://dx.doi.org/10.2196/19581
  15. World Health Organization. Regional Office for the Western Pacific. The Asia-Pacific perspective: redefining obesity and its treatment [Internet]. Sydney: Health Communications Australia; 2000 [cited 2023]. Available from: https://iris.who.int/handle/10665/206936 
  16. Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res Clin Pract [Internet]. 2020;167(108382):108382. Available from: http://dx.doi.org/10.1016/j.diabres.2020.108382 
  17. Alkundi A, Mahmoud I, Musa A, Naveed S, Alshawwaf M. Clinical characteristics, and outcomes of COVID-19 hospitalized patients with diabetes in the United Kingdom: A retrospective single centre study. Diabetes Res Clin Pract [Internet]. 2020;165(108263):108263. Available from: http://dx.doi.org/10.1016/j.diabres.2020.108263 
  18. World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020 [Internet]. World Health Organization; 2020 [cited 2023]. Available from: https://iris.who.int/handle/10665/332196 
  19. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M, et al. Radiological society of North America expert consensus document on reporting chest CT findings related to COVID-19: Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. Radiol Cardiothorac Imaging [Internet]. 2020;2(2):e200152. Available from: http://dx.doi.org/10.1148/ryct.2020200152 
  20. Chang MC, Park Y-K, Kim B-O, Park D. Risk factors for disease progression in COVID-19 patients. BMC Infect Dis [Internet]. 2020;20(1):445. Available from: http://dx.doi.org/10.1186/s12879-020-05144-x 
  21. de Almeida-Pititto B, Dualib PM, Zajdenverg L, Dantas JR, de Souza FD, Rodacki M, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension, and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr [Internet]. 2020;12(1):75. Available from: http://dx.doi.org/10.1186/s13098-020-00586-4 
  22. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension [Internet]. 2018;71(6):e13–115. Available from: http://dx.doi.org/10.1161/HYP.0000000000000065 
  23. Barber TM. COVID-19 and diabetes mellitus: implications for prognosis and clinical management. Expert Rev Endocrinol Metab [Internet]. 2020;15(4):227–36. Available from: http://dx.doi.org/10.1080/17446651.2020.1774360 
  24. Zhu L, She Z-G, Cheng X, Qin J-J, Zhang X-J, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab [Internet]. 2020;31(6):1068-1077.e3. Available from: http://dx.doi.org/10.1016/j.cmet.2020.04.021 
  25. American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2020. Diabetes Care [Internet]. 2020;43(Suppl 1):S14–31. Available from: http://dx.doi.org/10.2337/dc20-S002 
  26. Smith DL, Grenier J-P, Batte C, Spieler B. A characteristic chest radiographic pattern in the setting of the COVID-19 pandemic. Radiol Cardiothorac Imaging [Internet]. 2020;2(5):e200280. Available from: http://dx.doi.org/10.1148/ryct.2020200280 
  27. Huang Y, Lu Y, Huang Y-M, Wang M, Ling W, Sui Y, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism [Internet]. 2020;113(154378):154378. Available from: http://dx.doi.org/10.1016/j.metabol.2020.154378 
  28. Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19: A systematic review. Diabetes Metab Syndr [Internet]. 2020;14(4):655–9. Available from: http://dx.doi.org/10.1016/j.dsx.2020.05.020 
  29. Muniyappa R, Gubbi S. COVID-19 pandemic, corona viruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;E736–41.
  30. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr [Internet]. 2020;14(3):211–2. Available from: http://dx.doi.org/10.1016/j.dsx.2020.03.002 
  31. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care [Internet]. 2020;24(1):422. Available from: http://dx.doi.org/10.1186/s13054-020-03120-0 
  32. Saeed O, Castagna F, Agalliu I, Xue X, Patel SR, Rochlani Y, et al. Statin use and in-hospital mortality in patients with diabetes mellitus and COVID-19. J Am Heart Assoc [Internet]. 2020;9(24):e018475. Available from: http://dx.doi.org/10.1161/JAHA.120.018475 
  33. Tan WYT, Young BE, Lye DC, Chew DEK, Dalan R. Statin use is associated with lower disease severity in COVID-19 infection. Sci Rep [Internet]. 2020;10(1):17458. Available from: http://dx.doi.org/10.1038/s41598-020-74492-0 
  34. Mitacchione G, Schiavone M, Curnis A, Arca M, Antinori S, Gasperetti A, et al. Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy. J Clin Lipidol [Internet]. 2021;15(1):68–78. Available from: http://dx.doi.org/10.1016/j.jacl.2020.12.008
  35. Reshad RAI, Riana SH, Chowdhury MA-B, Moin AT, Miah F, Sarkar B, et al. Diabetes in COVID-19 patients: challenges and possible management strategies. Egypt J Bronchol [Internet]. 2021;15(1). Available from: http://dx.doi.org/10.1186/s43168-021-00099-2 

Articles related to the one you are viewing

There are currently no results to show, please try again later

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.